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OBJECTIVE The purpose of this study was to evaluate the safety of oligodendrocyte progenitor cells (LCTOPC1) derived
from human pluripotent stem cells administered between 7 and 14 days postinjury to patients with T3 to T11 neurologically
complete spinal cord injury (SCI). The rationale for this first-in-human trial was based on evidence that administration of
LCTOPC1 supports survival and potential repair of key cellular components and architecture at the SCI site.
METHODS This study was a multisite, open-label, single-arm interventional clinical trial. Participants (n = 5) received
a single intraparenchymal injection of 2 × 106 LCTOPC1 caudal to the epicenter of injury using a syringe positioning
device. Immunosuppression with tacrolimus was administered for a total of 60 days. Participants were followed with
annual in-person examinations and MRI for 5 years at the time of this report and will be followed with annual telephone
questionnaires for 6 to 15 years postinjection. The primary endpoint was safety, as measured by the frequency and
severity of adverse events related to the LCTOPC1 injection, the injection procedure, and/or the concomitant immunosuppression administered. The secondary endpoint was neurological function as measured by sensory scores and
lower-extremity motor scores as measured by the International Standards for Neurological Classification of Spinal Cord
Injury examinations.
RESULTS No unanticipated serious adverse events related to LCTOPC1 have been reported with 98% follow-up of
participants (49 of 50 annual visits) through the first 10 years of the clinical trial. There was no evidence of neurological
decline, enlarging masses, further spinal cord damage, or syrinx formation. MRI results during the long-term follow-up
period in patients administered LCTOPC1 cells showed that 80% of patients demonstrated T2 signal changes consistent
with the formation of a tissue matrix at the injury site.
CONCLUSIONS This study provides crucial first-in-human safety data supporting the pursuit of future human embryonic stem cell–derived therapies. While we cannot exclude the possibility of future adverse events, the experience
in this trial provides evidence that this cell type can be well tolerated by patients, with an event-free period of up to
10 years. Based on the safety profile of LCTOPC1 obtained in this study, a cervical dose escalation trial was initiated
(NCT02302157).
Clinical trial registration no.: NCT01217008 (clinicaltrials.gov)
https://thejns.org/doi/abs/10.3171/2021.12.SPINE21622

KEYWORDS spinal cord injury; GRNOPC1; LCTOPC1; AST-OPC1; human embryonic stem cells; clinical trials; central
nervous system; trauma; thoracic
ABBREVIATIONS AE = adverse event; AIS = American Spinal Injury Association Impairment Scale; DSMB = Data and Safety Monitoring Board; hESC = human embryonic stem cell; HLA = human leukocyte antigen; IND = Investigational New Drug; ISNCSCI = International Standards for Neurological Classification of Spinal Cord Injury;
LEMS = lower-extremity motor score; NLI = neurological level of injury; SAE = serious AE; SCI = spinal cord injury; UEMS = upper-extremity motor score; UTI = urinary
tract infection; ZPP = zone of partial preservation.
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T

o date, there are no treatments approved by the FDA
to induce neurological recovery following spinal
cord injury (SCI). Several interventions, including
glucocorticoids,1 modulation of voltage-gated channels,1–3
tetracycline antibiotics,4 and cell-based therapies,5–7 have
been studied in clinical trials; however, none to date have
met critical registration endpoints. In this report we describe what is to our knowledge the first-in-human phase
1 safety clinical trial of oligodendrocyte progenitor cells
(LCTOPC1) derived from human pluripotent stem cells,
which have mechanistic properties to support survival and
potential repair of key cellular components and architecture at the SCI site.
The initial characterization of the LCTOPC1 population was reported by Nistor et al. in 2005,8 who showed
that these cells could differentiate into oligodendroglial
progenitors. Subsequent studies in an acute incomplete
rat contusion injury model demonstrated that the oligodendroglial progenitor cells survived after delivery to
the SCI site9 and led to remyelination of denuded axons.
When delivered in the acute injury period, the cells led to
improvement in locomotor function as measured in standardized behavioral testing.9 Based on proof-of-principle
study data, preclinical studies were conducted to support
translation into safety clinical trials. Preclinical studies
demonstrated that the intended clinical, cryopreserved,
human equivalent dose formulation of LCTOPC1 could
survive and migrate after injection in the SCI site, produce
neurotrophic factors to support cell survival, and provide
remyelination potential to support denuded axons at the
SCI contusion site.10 Moreover, studies demonstrated that
the cells did not produce teratomas and did not lead to
increased pain in injured animals.10
The data from these studies formed the foundation for an
Investigational New Drug (IND) application to initiate this
phase 1 clinical trial, which was reviewed by the FDA, the
Data and Safety Monitoring Board (DSMB), the SCI clinical community, surgical and outcomes steering committees, internal and external ethics committees, internal and
clinical trial site stem cell research oversight committees,
and the IRB for each participating clinical trial site. There
was consensus that the data supported clinical testing in
patients with acute, complete, thoracic spinal cord lesions.
As a first-in-human study, the trial design accounted for the
need to minimize the risk to participants, and hence individuals with complete SCI localized between the thoracic
neurological levels T3 and T11 were chosen for intervention. The trial was an open-label, unblinded, nonrandomized, non–placebo-controlled study performed to establish
the safety of intraparenchymal injection of LCTOPC1 and
to monitor changes in neurological function.
Determining the long-term safety of stem cell therapeutic agents is a critical step in enabling future trials
to investigate the use of novel stem cell or combination
therapies. Ten years postimplantation, there have been
no medical or neurological complications to indicate that
LCTOPC1 implantation is unsafe. Specifically, there have
been no serious adverse events (SAEs) related to the procedure, cell implant, or immunosuppression. In addition,
there have been no significant changes in neurological
function. Safety data from this first-in-human study sup-
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port progression to a clinical trial for individuals with cervical SCIs.

Methods

Clinical Study Design
This study was a phase 1, multicenter, nonrandomized,
single-group assignment, interventional clinical trial. Participants were enrolled from one of seven centers in the
United States. The study was registered on clinicaltrials.
gov (NCT01217008).
The primary endpoint was safety, as measured by the
frequency and severity of adverse events (AEs) related to
LCTOPC1, the injection procedure used to administer
LCTOPC1, and/or the concomitant immunosuppression
administration. The secondary endpoint was neurological function as measured by sensory scores and lowerextremity motor scores (LEMSs) on the International
Standards for Neurological Classification of Spinal Cord
Injury (ISNCSCI) examinations. The eligibility criteria
are summarized in Supplemental Table 1. At the time of
this report, participants had been followed by protocol for
a total of 5 years of in-person visits and will continue to
be followed for an additional 10 years of annual telephone
visits. Figure 1 provides an overall study schema for the
clinical trial.
Study Oversight and Monitoring
In addition to FDA review, the protocol and study design
were reviewed by a steering committee. Due to the nature
of the study product, the protocol was also reviewed by
an overall study Embryonic Stem Cell Research Oversight
(ESCRO) committee as well as individual site ESCRO
committees where required. As noted above, safety monitoring occurred via an External Medical Monitor, Sponsor
Medical Monitor, and DSMB.
Informed Consent
The study was conducted in compliance with the protocols of the Declaration of Helsinki, and according to the
International Conference on Harmonization (ICH) Guidance for Industry, Good Clinical Practice (GCP): Consolidated Guidance (ICH E6), and all other regulatory and
institutional requirements, including those for subject privacy, informed consent, IRB or Independent Ethics Committee approval, and record retention.
Due to the potential for long-term risks of human embryonic stem cell (hESC) administration, two protocols
and thus two informed consent forms were required: one
for the administration of LCTOPC1 and 1-year follow-up
(CP35A007) and the other for follow-up from years 2 to
15 following product administration (CP35A008). Written
informed consent for both protocols was obtained for all
individuals prior to study enrollment.
Study Participants
Male or female participants from 18 to 65 years of age
with acute traumatic SCI were eligible for study participation. As this was a first-in-human study, with a risk of
neurological deterioration, inclusion was limited to neu-
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FIG. 1. Phase 1 clinical trial study schema. f/u = follow-up.

rologically complete injuries (American Spinal Injury Association Impairment Scale [AIS] grade A), with a single
neurological level of injury (NLI) from levels T3 to T10,
with no spared motor function in < 5 levels (i.e., zone of
partial preservation [ZPP]) below the single neurological
level. These inclusion criteria were chosen to minimize
loss of function if neurological deterioration were to occur.
Poststabilization MRI was used to confirm the presence of a single spinal cord lesion with sufficient visualization of the spinal cord for 30 mm above and below the
injury epicenter to enable postinjection safety monitoring.
Participants had to be eligible for an elective surgical procedure to inject LCTOPC1 between 7 and 14 days following SCI (Supplemental Table 1).
Investigational Product and Mode of Administration
LCTOPC1 is a cell population containing a mixture of
oligodendrocyte progenitor cells and other characterized
cell types that are obtained following differentiation of
undifferentiated hESCs from the H1 stem cell line, produced at the University of Wisconsin in 1998.11
LCTOPC1 is a cryopreserved cell therapy product.
At the time of cryopreservation, each vial contained 7.5
× 106 viable cells in 1.2 ml of cryoprotectant solution.
LCTOPC1 was supplied in 2.0-ml cryovials and shipped
to the clinical sites in the vapor phase of liquid nitrogen
and stored under the same conditions at the site. Prior to
administration, LCTOPC1 was thawed and prepared by
study personnel who were trained and qualified in the
preparation of the study drug.
Participants received a single administration of 2 × 106
viable LCTOPC1 cells suspended in Hanks’ Balanced
Salt Solution (HBSS), with a total volume per dose of 50
μl. The rationale for selection of this dose was based on
preclinical studies involving rats and mice and on dose
extrapolation to humans using two methods: 1) comparing the relative sizes of the human and rat spinal cords
and 2) evaluating tumorigenicity risks with respect to the
absolute number of injected cells. During the develop-

ment of LCTOPC1, a dose of 2 × 106 cells was the highest dose that was feasible to administer in the injured rat
spinal cord and the rat was the largest animal that could
be utilized to satisfy the animal number required for the
IND-enabling studies for this novel product. Hence, to be
conservative, 2 × 106 cells, the highest dose tested in rats,
was used as the dose for the phase 1 trial.
The intended route of administration for LCTOPC1 was
intraparenchymal at a depth of 6 mm in the midline and
5 mm caudal to the epicenter of injury as determined by
MRI, as modeled in preclinical studies.10 A caudal injection was selected out of an abundance of caution to avoid
any potential direct tissue damage above the injury level.
Based on preclinical studies, it was anticipated that the injected cells would migrate rostrally throughout the injury
site.10 The 7- to 14-day time frame was chosen based on
results of animal studies suggesting poor graft survival
for implantation within the first 7 days of injury9 while attempting to maximize the potential neuroprotective and remyelinating effect. A custom-designed syringe positioning
device (Supplemental Fig. 1) was utilized to assist neurosurgeons with the controlled delivery of the cells.12
Immunosuppression
Participants who received LCTOPC1 also received tacrolimus to prevent rejection of this allogeneic, cell-based
product. Immunosuppression with tacrolimus was initiated between 6 and 12 hours after injection of LCTOPC1.
If the participant was unable to take oral medication,
tacrolimus was administered intravenously at a starting
dose of 0.01 mg/kg/day, given as a continuous intravenous
infusion. Participants were switched to oral tacrolimus as
soon as possible. The starting dose for oral tacrolimus was
0.03 mg/kg/day, divided into 2 daily doses. The tacrolimus
dose was adjusted to achieve a target whole-blood trough
level of 3 to 7 ng/ml.
On day 46, the tacrolimus dose was decreased by 50%
(rounded to the nearest 0.5 mg, as this was the smallest
capsule size available). On day 53, the tacrolimus dose
J Neurosurg Spine Volume 37 • September 2022
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was decreased by another 50% (rounded to the nearest 0.5
mg). If the rounded total daily dose was 0.5 mg or lower,
the participant received a 0.5-mg dose once per day until
tacrolimus was discontinued. Tacrolimus was discontinued at day 60. The dose of tacrolimus was lowered if the
trough blood level exceeded 7 ng/ml. In addition, an expert reviewed all ISNCSCI examination forms to assess
whether there were any changes in neurological function
that may have been associated with tacrolimus tapering
and/or discontinuation.
Follow-Up and Assessments
An overview of study visits for the 1-year protocol
follow-up (CP35A007) and 2- to 15-year protocol followup (CP35A008) is provided in the study schema (Fig. 1).
As this was a first-in-human clinical trial of cells derived
from hESCs, a high number of study visits and long-term
follow-up were required. In the 1-year protocol, three
study visits were required prior to product administration,
with 13 evaluations in the first year following study administration (Supplemental Tables 2 and 3). For the longterm protocol, annual visits were required in years 2–5.
Subsequent to the year 5 annual visit, follow-up was by
annual telephone questionnaires (Supplemental Document
1) and in-person evaluations, as necessary. Telephone assessments included documentation of all new medications
taken for longer than 30 days, admissions to the hospital,
and documentation of SAEs and AEs.
Safety Assessments
The primary endpoint of the phase 1 clinical trial was
safety, as measured by the frequency and severity of AEs
within 1 year of LCTOPC1 injection that were related to
LCTOPC1, the injection procedure used to administer
LCTOPC1, and/or the concomitant immunosuppression
administration. Safety assessments included physical examination, vital signs, ISNCSCI neurological examination,
pain questionnaire, electrocardiogram, MRI, laboratory
tests for hematology and blood chemistry, laboratory tests
for immunosuppression safety monitoring (whole-blood
trough levels of tacrolimus and serum levels of creatinine,
potassium, magnesium, phosphate, ionized calcium, aspartate aminotransferase, alanine aminotransferase, and
total bilirubin), concomitant medications, and AEs. The
severity of AEs and the characterization of SAEs were
evaluated using standard FDA criteria.13
Neurological Assessments
The secondary endpoint was neurological function,
including measurement of sensory scores and LEMSs.
Neurological function was evaluated using the ISNCSCI
examination for motor and sensory testing and for designation of the AIS grade.14
Exploratory Endpoints
Pain assessment was performed using the International
Spinal Cord Injury Pain Basic Data Set.15,16 A set of three
questions was added to assess allodynia. These questions
covered the presence and severity of pain provoked or increased by brushing, pressure, or contact with cold. Infor324

mation on pain medication was collected as part of the
assessment of concomitant medications.
Magnetic Resonance Imaging
Screening/baseline MRI was obtained between 3 and 5
days prior to injection (day −3 and day −5) of LCTOPC1
but no earlier than 4 days after SCI. The screening/baseline MRI included the brain, cerebellum, and entire spinal cord, with and without contrast (gadolinium-diethylenetriamine pentaacetic acid [Gd-DTPA]). If surgery for
LCTOPC1 injection was subsequently delayed for more
than 3 days, then a repeat MRI of the thoracic spine, without contrast, was obtained. Follow-up MRI scans of the
spinal cord and cerebellum, with and without contrast
(Gd-DTPA), were obtained on days 7, 60, 120, and 270
postinjection. A full central nervous system MRI, with
and without contrast (Gd-DTPA), was obtained on days
30, 90, 180, and 365, as well as yearly between years 2 and
5. Image acquisition protocols were standardized. Image
review was centralized and standardized by an independent radiologist at Radiology Imaging Associates Denver.
Human Leukocyte Antigen Typing and Immunological
Monitoring
LCTOPC1 cells do not express human leukocyte antigen (HLA) class II and are resistant to NK-cell lysis.17
However, one concern with the safety and potential efficacy of LCTOPC1 was the possibility of allogeneic rejection by the host’s immune system. Immunosuppression
was minimized in terms of duration to 60 days and dosed
below the typical long-term maintenance therapy levels
used for solid organ transplantation.
Peripheral blood and CSF samples from LCTOPC1injected participants were collected according to protocol.
A lumbar puncture to obtain 10 ml of CSF was conducted
after receiving general anesthesia but prior to LCTOPC1
injection as well as at day 60 postinjection to assess for
rejection of allogeneic cells as well as for immunological
monitoring. The following CSF assessments occurred at
the hospital laboratory: white blood cell count, glucose,
total protein, oligoclonal banding, myelin basic protein,
and immunoglobulin G index. In addition, CSF was evaluated by the sponsor to further assess immune response to
LCTOPC1 and for the presence of LCTOPC1 (day 60) using a polymerase chain reaction–based assay. Peripheral
blood was examined for the presence of antibodies specific for the donor-specific HLA molecules on LCTOPC1
and to detect T-cell–mediated responses to LCTOPC1.
Statistical Methods
Descriptive analysis was used due to the small sample
size and the open-label and nonrandomized study design.
The primary and secondary endpoints of this study are
presented descriptively in table, figure, and text form.

Results

Study Participants
The first participant received implantation during the
winter of 2010, and the last participant was enrolled in the
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FIG. 2. Participant screening, treatment, and follow-up through the phase 1 clinical trial. DVT = deep vein thrombosis.

winter of 2011. Eleven patients with SCI were screened
for enrollment, 6 of whom failed screening: 4 due to MRI
artifacts which prohibited adequate spinal cord visualization, 1 based on the ISNCSCI examination (NLI T1), and
1 due to elevated liver enzymes. A total of 5 patients with
SCI received LCTOPC1 at three study sites. Figure 2 provides a Consolidated Standard of Reporting Trials (CONSORT) flow diagram.
In this trial, the most common mechanism of injury
was motor vehicle related for 4 of 5 patients, with a fall
being the cause of injury in 1 patient. Four of 5 participants enrolled were male. The cohort age ranged from 21
to 32 years.
Participant Follow-Up
At the time of this report, all participants had completed
their 10th year of follow-up. In agreement with the FDA,
TABLE 1. AEs and SAEs
AE & SAE System Organ Class
Preferred Term

No. of
Events

No. (%) of
Pts (n = 5)

All events
Nervous system disorders
Eye disorders
Gastrointestinal disorders
General disorders & administration site conditions
Immune system disorders
Infections & infestations
Injury, poisoning, & procedural complications
Investigations
Metabolism & nutrition disorders
Musculoskeletal & connective tissue disorders
Psychiatric disorders
Renal & urinary disorders
Reproductive system & breast disorders
Respiratory, thoracic, & mediastinal disorders
Skin & subcutaneous tissue disorders
Surgical & medical procedures
Vascular disorders

174
19
2
16
8

4 (80.0)
2 (40.0)
5 (100)
3 (60.0)

2
42
10
5
3
33
8
7
1
2
11
2
3

2 (40.0)
5 (100)
5 (100)
3 (60.0)
2 (40.0)
5 (100)
2 (40.0)
4 (80.0)
1 (20.0)
2 (40.0)
3 (60.0)
2 (40.0)
2 (40.0)

Pt = patient.

the trial was structured to begin with 5 years of in-person
evaluation followed in years 6 through 15 with telephone
interviews. During the first 5 years of the study, 24 of 25
in-person annual visits were completed. One participant
did not participate in the year 5 in-person visit but has
participated in scheduled telephone follow-up. From year
6 to the current time, 25 of 25 annual telephone interviews
have been completed. All 5 participants have completed
10 years of follow-up interviews.
Primary Outcome Measure: Evaluation of Safety
All SAEs and AEs (related and unrelated to procedure,
cell implant, or immunosuppression) are summarized in
Table 1 and described below.
SAEs Related to Procedure, Cell Implant, or
Immunosuppression
There were no SAEs related to the procedure, cell implant, or immunosuppression. There were no findings of
clinical concern on MRI scans of the full central nervous
system through 5 years postinjection in any participant.
During long-term telephone follow-up, participants denied
having any fever of unknown cause or any changes in sensation in chest, arms, or legs (other than described below),
and no participants have been diagnosed with any type
of cancer. No participants died during the study. Safety
events were monitored by the DSMB and no suspension
rules were triggered.
SAEs Unrelated to Procedure, Cell Implant, or
Immunosuppression
Three participants have reported 4 SAEs unrelated to
the procedure, cell implant, or immunosuppression. These
SAEs included urinary tract infection (UTI) and subsequent transitory autonomic dysreflexia in 1 patient, pyelonephritis in 1 patient, and a mood disorder in 1 patient.
AEs Related to Procedure, Cell Implant, or
Immunosuppression
AEs Categorized by Grade
Over the course of the trial, 25 AEs were judged by the
investigators to be possibly related to LCTOPC1 (grade
1/mild [n = 9], grade 2/moderate [n = 15], and grade 3/
severe [n = 1]). The grade 3 AE was described as a burning
sensation in the trunk and lower extremities first reported
J Neurosurg Spine Volume 37 • September 2022
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on day 57 postinjection with grade 1 severity, increasing
to grade 3 severity on day 90 postinjection. This neuropathic pain resulted in 3 additional grade 2 severity AEs
and was ongoing through year 9 follow-up. Grade 2 AEs
included surgical site pain, hypomagnesemia, UTI, vaginal yeast infection, emesis, upper-back pain, shoulder pain,
pain with range of motion, and autonomic discomfort during catheterization relieved after treatment with lidocaine.
Grade 1 AEs included hypomagnesemia, UTI, fever, headache, nausea, and spasticity.
AEs Categorized by Relation to Procedure, Cell Implant, or
Immunosuppression

Nine of the 25 related AEs were deemed possibly related specifically to the injection procedure. Eight of the
9 were grade 1 or 2 in severity and 1 was grade 3. The
AEs were predominantly transient postoperative pain, 1
fever, and 1 UTI. There were no AEs attributed to the cell
implant. Moreover, the immunosuppression regiment was
well tolerated, and all 5 participants completed the regimen per protocol. Sixteen of the 25 AEs were deemed possibly related specifically to the immunosuppression. Seven
grade 1 AEs and 9 grade 2 AEs were judged to be possibly related specifically to tacrolimus. These AEs were
primarily known common adverse reactions to tacrolimus
(nausea/emesis, low magnesium level, infections). Among
reported infections, 1 of 7 was a vaginal yeast infection
and 6 of 7 infections were in the urinary tract, which is a
common complication of SCI.
AEs Unrelated to Procedure, Cell Implant, or
Immunosuppression
At year 6, 1 participant reported an increase in frequency and intensity of muscle spasms attributed to functional
electrical stimulation cycling. This participant reported
resolution of these symptoms during years 7 through
10 and is currently not using any medication for muscle
spasms. In year 9, a different individual received outpatient treatment after developing a deep vein thrombosis.
In the 10th year of follow-up, a third individual received
a baclofen pump and began taking oral medications for
migraines and type 2 diabetes.
Secondary Outcome Measure: Neurological Assessment
After discharge from acute inpatient rehabilitation and
through the first 5 years postimplantation, participants
continued to be evaluated in person according to the
schedule shown in Fig. 1 and Supplemental Tables 2 and
3. Of note, between baseline and year 5, participants’ annual in-person evaluations included at least 13 ISNCSCI
examinations. All participants had an AIS grade of A on
enrollment in the trial and all participants have maintained
the same impairment grade. The highest and lowest single
NLIs enrolled in the study were T3 and T8, respectively.
Only the individual with T3 NLI improved to T4 with a
sensory ZPP initially at T4 bilaterally noted to improve to
T5 on the left and T6 on the right at 1-year follow-up. In total, 3 of 5 participants experienced at least one level of improvement in their ZPP. All participants began and ended
the 5 years of in-person ISNCSCI examination with intact
326

upper-extremity motor function with an upper-extremity
motor score (UEMS) of 50 out of 50 and an LEMS of 0
out of 50 (Table 2). Over the course of 5 years of in-person
follow-up, sensory examination results have not materially
changed. Figure 3 provides a diagrammatic representation of the motor and/or sensory function of each patient
at baseline and at 5 years post–LCTOPC1 administration.
MRI Findings
No participant exhibited evidence of an enlarging cyst,
enlarging mass, spinal cord damage related to the injection
procedure, intramedullary hemorrhage, CSF leak, epidural abscess or infection, inflammatory lesions in the spinal
cord, CSF flow obstruction, or masses in the ventricular
system. No evidence of any adverse neurological changes
or adverse changes on MRI was reported during tacrolimus tapering or after tacrolimus discontinuation. MRI
results during the long-term follow-up period in patients
administered LCTOPC1 cells showed that 80% of patients
demonstrated T2 signal changes consistent with the formation of a tissue matrix at the injury site.
Immune Monitoring
LCTOPC1 is an allogeneic cell therapy and is potentially sensitive to rejection by the recipient immune system. As a baseline assessment, HLA class I and class II
molecular typing was performed for 10 alleles of the donor
LCTOPC1 cells and peripheral blood cells of each of the
5 recipients. The potential development of a cellular immune response to LCTOPC1 was assessed and showed no
evidence of T-cell–mediated responses to LCTOPC1 even
after cessation of tacrolimus immunosuppression in any
of the serum samples of the 5 recipients. In addition, CSF
samples obtained through lumbar puncture did not show
signs of antibody or T-cell responses to LCTOPC1.

Discussion

In January of 2009, the journal Nature reported that
LCTOPC1 would enter “the world’s first clinical trial of
a therapy generated by human embryonic stem cells.”18 At
the time, pharmaceutical research in acute SCI was considered a relatively recent development.19 Although no clinical trial of hESC-derived cell lines had ever been assessed
in any context, procedures for other intraparenchymal
injections of cellular products (e.g., activated autologous
macrophages) into the spinal cord had been evaluated,6
providing a partial roadmap for LCTOPC1-based studies.
We present the primary and secondary outcome measures of 5 participants who received 2 × 106 allogeneic
hESC-derived oligodendrocyte progenitor cells within
7–14 days postinjury. The primary results from the first 10
years of follow-up establish the safety and feasibility of intraparenchymal LCTOPC1 injection. The injection procedure and the low-dose immunosuppression regimen were
well tolerated. At the time of this report, all 5 participants
who received LCTOPC1 had demonstrated no evidence
of neurological deterioration or adverse findings on MRI
scans. No unanticipated SAEs related to LCTOPC1 have
been reported with 98% follow-up of participants (49 of 50
annual visits) through the first 10 years of the clinical trial.
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TABLE 2. ISNCSCI exam results at baseline and years 1 and 5
Sensory
Study Visit
Pt 1
Baseline
Yr 1
Yr 5
Pt 2
Baseline
Day 270*
Yr 5
Pt 3
Baseline
Yr 1
Yr 4*
Pt 4
Baseline
Yr 1
Yr 5
Pt 5
Baseline
Yr 1
Yr 5

Neurological Level
Motor

ZPP
Sensory

Motor

TSS

UEMS

LEMS

Rt

Lt

Rt

Lt

NLI

Rt

Lt

Rt

Lt

AIS Grade

ND
111
111

ND
50
50

0
0
0

T6
T6
T7

ND
T7
T6

T6
T6
T7

ND
T7
T6

ND
T6
T6

T7
T7
T7

T7
T7
T7

T6
T6
T7

ND
T7
T6

A
A
A

125
129
122

50
50
50

0
0
0

T8
T8
T7

T8
T8
T7

T8
T8
T7

T8
T8
T7

T8
T8
T7

T9
T10
T10

T9
T10
T10

T8
T8
T7

T8
T8
T7

A
A
A

112
112
114

50
50
50

0
0
0

T6
T6
T6

T6
T6
T7

T6
T6
T6

T6
T6
T7

T6
T6
T6

T8
T8
T8

T8
T8
T8

T6
T6
T6

T6
T6
T7

A
A
A

121
123
123

50
50
50

0
0
0

T7
T7
T7

T8
T8
T8

T7
T7
T7

T8
T8
T8

T7
T7
T7

T8
T9
T9

T9
T10
T9

T7
T7
T7

T8
T8
T8

A
A
A

82
95
97

50
50
50

0
0
0

T3
T4
T4

T3
T4
T5

T3
T4
T4

T3
T4
T5

T3
T4
T4

T4
T6
T6

T4
T5
T6

T3
T4
T4

T3
T4
T5

A
A
A

ND = unable to determine; TSS = total sensory score.
All 5 patients were AIS grade A at enrollment and there were no conversions to AIS B. The highest single and lowest NLIs enrolled in the study were T3 and T8,
respectively. Only the patient with the T3 NLI improved to T4, with a sensory ZPP initially at T4 bilaterally noted to improve to T5 on the left and T6 on the right at 1-year
follow-up. In total, 3 of 5 patients experienced at least 1 level of improvement in their ZPP.
* Patients were not able to follow up as directed.

Although this study did not demonstrate significant recovery, no participant exhibited evidence of neurological deterioration on ISNCSCI examinations through 5 years of
in-person follow-up or 10 years of self-reported neurological function. It is important to note that potentially subtle
changes in neurological function (better or worse) could
occur that are not measurable by the ISNCSCI of the participants. In addition, there was a male sex predominance
in this study cohort, which may potentially have implications for the generalizability of these results.
This study was not designed to assess efficacy; however,
animal studies of LCTOPC1 produced improvements in
motor function through mechanisms that appeared to represent remyelination as well as neuroprotection, suppression of inﬂammation, promotion of axonal regeneration,
and/or homeostatic maintenance.9,20 The proposed mechanism of locomotor function improvement included remyelination as well as expression of neurotrophic factors.21 The
limited signs of functional recovery in various human trials
despite promising results in animals may be related to the
relative severity of human injuries in comparison to preclinical studies with incomplete contusion, suggesting that
subsequent studies with incomplete injuries may demonstrate recovery more similar to that seen in animal models.
Neuropathic pain in response to LCTOPC1 secondary
to remyelination or neurotrophic factors was assessed us-

ing the International Spinal Cord Injury Pain Basic Data
Set and a set of three questions to assess allodynia. Neuropathic at-level pain and below-level pain often have onset
during the first several months after SCI, and by 1 year
the prevalence of neuropathic pain approaches 60%.22
The prevalence of pain in this study is consistent with the
natural history of neuropathic pain. One participant experienced neuropathic pain reported as a burning sensation in the trunk and lower extremities that was considered
possibly related to LCTOPC1, which persisted in longterm follow-up. The pain reported by this participant is
consistent with two of the major categories of pain that are
common following SCI: neuropathic pain at the level of
injury (termed neuropathic at-level pain), and neuropathic
pain that occurs diffusely below the level of injury (termed
neuropathic below-level pain).23 Unfortunately for affected
individuals, both at-level and below-level neuropathic pain
are often severe and persistent for at least 5 years after SCI,
despite attempts at pain management.24 In addition, 40%
to 50% of individuals with these types of pain report their
pain as severe or excruciating.25 It is not possible to determine a cause-and-effect relationship between LCTOPC1
and a change in the incidence of long-term neuropathic
pain in this small, open-label study.
Serial MRI studies did not demonstrate the formation
of ectopic tissue and/or teratomas. In addition to the abJ Neurosurg Spine Volume 37 • September 2022
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FIG. 3. ISNCSCI pretransplantation (baseline) and at year 5 for each of the 5 study patients. Green represents areas with normal
motor and/or sensation, red represents areas with absent motor and/or sensation, orange areas represent sensation that is present but abnormal. *Participant 3 did not participate in year 5 follow-up; year 4 data are presented.
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sence of space-occupying lesions, the natural history of
chronic SCI MRI studies suggests that cavitary lesions
will be identifiable in 58% of individuals who pursue thoracic-level cellular trials.26 MRI results during the longterm follow-up period for LCTOPC1 were of particular
significance because 80% of individuals showed T2 signal
changes consistent with the formation of a tissue matrix at
the injury site. Although the sample size is limited, these
findings suggest that LCTOPC1 cells may have either
durable engraftment and/or induced long-term changes
which limited cavitation at the injury site.27
SCI is a relatively rare condition and the potential population of patients with T3–11 AIS grade A injuries represents less than 20% of acute SCI patients in the United
States.28 Despite the development of a nationwide network
of seven treatment sites, the complexities of identification,
consent, and implantation required more than 1 year to enroll 5 participants. In November 2011, the initial corporate
sponsor, Geron Corporation, halted the trial before reaching the intended 8-participant cohort size, citing difficulty
raising capital.29 The stem cell program was ultimately
acquired by Asterias Biotherapeutics, which initiated the
Dose Escalation Study in Spinal Cord Injury clinical trial,
enrolling individuals with cervical complete and sensory
incomplete injuries (NCT02302157).

Conclusions

The LCTOPC1 thoracic SCI clinical trial is one of
the longest-running clinical trials in the hESC field. The
study provides crucial first-in-human safety data for future
hESC-derived therapies. While we cannot exclude the possibility of future AEs, the experience in this trial provides
evidence that these treatments can be well tolerated and
event free for up to 10 years. In addition, this report supports the willingness of individuals to participate in longterm follow-up as well as setting a standard for corporate
sponsors’ commitment to data collection beyond their immediate financial interests. Based on the safety profile of
LCTOPC1 obtained in this study, a cervical dose escalation trial was initiated (NCT02302157).
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